Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT

The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. CYBN a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and their pharmaceutical compositions with exclusivity until 2041. 

Considering the recently granted patent covering its clinically advanced compounds psilocybin analog CYB003 and DMT analog CYB004 as well as its announced intention to acquire U.K. short-acting psychedelics developer Small Pharma DMTTF, Cybin rightly claims the new grant strengthens its forefront position within the development of “potential, best-in-class deuterated, tryptamine-based therapeutics for the treatment of mental health conditions.”

See Also: Treating PTSD Topically & Directly To The Brain? Psychedelics Delivery Company Poised For Major Breakthrough

CEO Doug Drysdale views this patent issuance as “timely” regarding the definitive agreement with Small Pharma, a merger that would create the “most impressive and robust” intellectual property portfolio within the psychedelics industry. In numbers, that is a reported total of 29 patents granted and 150+ pending.

Further, “the strong synergy” of the collective IP provides “an unparalleled opportunity” to develop novel, differentiated therapeutics for patients in need of improved treatment options, Drysdale says.

Upcoming clinical milestones include:

• Phase 1 deuterated DMT data in Q3/Q4 2023, expected to guide the formulation and administration routes toward a Phase 2 efficacy study in early 2024.

• Phase 2 topline efficacy data for CYB003 in Major Depressive Disorder (MDD) and topline Phase 1 data from the CYB004-E study are expected in Q3/Q4 2023.

• FDA submission of CYB003 Phase 1/2 data for pivotal studies expected following topline efficacy data readout.

• Preparations are underway toward scaling to a potential Phase 3 CYB003 study in early 2024.

• Interested in other natural medicines markets? Our biannual, absolute crowd-puller Cannabis Capital Conference is coming up! Whether to close your deals or just get acquainted with the sector’s best, come join us this Sept. 27-28 in Chicago for our 17th edition! Tickets HERE.

• Photo: Benzinga edit with photo by PopTika on Shutterstock and Harbin on Wikimedia Commons.